Maarten A. D. H. Schalekamp

Maarten A. D. H. Schalekamp's AcademicInfluence.com Rankings

Medical

#2556

World Rank

#2984

Historical Rank

Epidemiology

#470

World Rank

#492

Historical Rank

medical Degrees

Download Badge

Medical

Maarten A. D. H. Schalekamp's Degrees

PhD Epidemiology Erasmus University Rotterdam
Masters Epidemiology Erasmus University Rotterdam
Bachelors Biomedical Sciences Leiden University

Why Is Maarten A. D. H. Schalekamp Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Maarten A. D. H. Schalekamp's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Arterial Stiffness and Risk of Coronary Heart Disease and Stroke: The Rotterdam Study (2006) (1843)
Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. (1995) (807)
Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. (1994) (321)
Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. (1989) (286)
Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. (1996) (263)
Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans (1998) (245)
Determination of catecholamines in human plasma by high-performance liquid chromatography: comparison between a new method with fluorescence detection and an established method with electrochemical detection. (1989) (226)
Angiotensin levels in the eye. (1994) (224)
Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions. (1998) (208)
Metabolism and Production of Angiotensin I in Different Vascular Beds in Subjects With Hypertension (1990) (203)
A Clinical Prediction Rule for Renal Artery Stenosis (1998) (195)
Angiotensin II type 1 (AT1) receptor-mediated accumulation of angiotensin II in tissues and its intracellular half-life in vivo. (1997) (192)
Intrarenal angiotensin II: interstitial and cellular levels and site of production. (2001) (190)
Hypertension in chronic renal failure. An abnormal relation between sodium and the renin-angiotensin system. (1973) (171)
Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. (1997) (170)
Mannose 6-phosphate receptor-mediated internalization and activation of prorenin by cardiac cells. (1997) (162)
Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin I. (1997) (157)
Angiotensin II-mediated growth and antigrowth effects in cultured neonatal rat cardiac myocytes and fibroblasts. (1997) (156)
Immunoreactive renin, prorenin, and enzymatically active renin in plasma during pregnancy and in women taking oral contraceptives. (1986) (154)
Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus (1999) (153)
C-reactive protein and arterial stiffness in older adults: the Rotterdam Study. (2004) (148)
Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? (1992) (141)
Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure. (1997) (140)
Asynchronous changes in prorenin and renin secretion after captopril in patients with renal artery stenosis. (1983) (140)
Angiotensin-Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Blockade Prevent Cardiac Remodeling in Pigs After Myocardial Infarction: Role of Tissue Angiotensin II (2000) (134)
Arterial stiffness as the candidate underlying mechanism for postural blood pressure changes and orthostatic hypotension in older adults: the Rotterdam Study (2006) (133)
AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. (1998) (131)
Splint renal function after captopril in unilateral renal artery stenosis. (1984) (127)
Renal artery stenosis and hypertension (1994) (126)
Renal artery stenosis and hypertension. (1994) (124)
Abnormal relation between exchangeable sodium and the renin-angiotensin system in malignant hypertension and in hypertension with chronic renal failure. (1973) (122)
Abnormal renal haemodynamics and renin suppression in hypertensive patients. (1970) (120)
Plasma semicarbazide-sensitive amine oxidase activity is elevated in diabetes mellitus and correlates with glycosylated haemoglobin. (1995) (119)
High-affinity prorenin binding to cardiac man-6-P/IGF-II receptors precedes proteolytic activation to renin. (2001) (116)
Studies on the mechanism of hypernatriuresis in essential hypertension in relation to measurements of plasma renin concentration, body fluid compartments and renal function. (1971) (116)
Optimal collection and storage conditions for catecholamine measurements in human plasma and urine. (1993) (114)
Renal hemodynamics and the renin-angiotensin-aldosterone system in normotensive subjects with hypertensive and normotensive parents. (1991) (113)
Prorenin-Induced Myocyte Proliferation: No Role for Intracellular Angiotensin II (2002) (112)
High plasma prorenin in diabetes mellitus and its correlation with some complications. (1990) (110)
How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism. (1982) (106)
Hemodynamic changes during long‐term thiazide treatment of essential hypertension in responders and nonresponders (1980) (104)
Regional angiotensin II production in essential hypertension and renal artery stenosis. (1993) (103)
Vasoconstriction by in situ formed angiotensin II: role of ACE and chymase. (1999) (99)
Production of angiotensins I and II at tissue sites in intact pigs. (1992) (98)
Pindolol acts as beta-adrenoceptor agonist in orthostatic hypotension: therapeutic implications. (1981) (98)
Effects of an angiotensin-converting enzyme inhibitor (captopril) on blood pressure in anephric subjects. (1980) (98)
Control of enzymatically inactive renin in man under various pathological conditions: implications for the interpretation of renin measurements in peripheral and renal venous plasma. (1978) (95)
Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist. (1982) (91)
Opposite effects of captopril on angiotensin I-converting enzyme 'activity' and 'concentration'; relation between enzyme inhibition and long-term blood pressure response. (1981) (90)
Source of plasma prorenin in early and late pregnancy: observations in a patient with primary ovarian failure. (1987) (89)
Cultured neonatal rat cardiac myocytes and fibroblasts do not synthesize renin or angiotensinogen: evidence for stretch-induced cardiomyocyte hypertrophy independent of angiotensin II. (1999) (88)
Prorenin Accumulation and Activation in Human Endothelial Cells: Importance of Mannose 6-Phosphate Receptors (2001) (87)
Localization and production of angiotensin II in the isolated perfused rat heart. (1998) (86)
5-HT, alpha-adrenoceptors, and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency. (1984) (86)
An intrinsic factor XII–prekallikrein-dependent pathway activates the human plasma renin–angiotensin system (1979) (85)
An intrinsic factor XII–prekallikrein-dependent pathway activates the human plasma renin–angiotensin system (1979) (85)
Plasma thyroxine, 3,3',5-triiodothyronine and 3,3',5'-triiodothyronine during beta-adrenergic blockade in hyperthyroidism. (1977) (85)
Subcellular localization of angiotensin II in kidney and adrenal (2001) (84)
Body-fluid volume in low-renin hypertension. (1974) (84)
Effects of Selective and Nonselective β-Agonists on Plasma Potassium and Norepinephrine (1984) (83)
Effects of 10 Different β‐Adrenoceptor Antagonists on Hemodynamics, Plasma Renin Activity, and Plasma Norepinephrine in Hypertension: The Key Role of Vascular Resistance Changes in Relation to Partial Agonist Activity (1983) (80)
Clinical validation of renin monoclonal antibody-based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity. (1996) (77)
Identification and quantification of renin and prorenin in the bovine eye. (1990) (76)
Sodium and the renin-angiotensin system in essential hypertension and mineralocorticoid excess. (1974) (75)
Sodium restriction and potassium supplementation in young people with mildly elevated blood pressure. (1987) (75)
Do beta-blockers really increase peripheral vascular resistance? Review of the literature and new observations under basal conditions. (1988) (73)
Uptake and proteolytic activation of prorenin by cultured human endothelial cells. (1999) (72)
Elevated plasma noradrenaline in response to beta-adrenoceptor stimulation in man. (1982) (72)
Two-step prorenin-renin conversion. Isolation of an intermediary form of activated prorenin. (1987) (70)
Comparison of Finapres non-invasive beat-to-beat finger blood pressure with intrabrachial artery pressure during and after bicycle ergometry. (1989) (70)
Cardiomyocytes Bind and Activate Native Human Prorenin: Role of Soluble Mannose 6-Phosphate Receptors (2001) (70)
Metabolism of angiotensin I by different tissues in the intact animal. (1992) (68)
Renal abnormality of essential hypertension. (1974) (67)
Cyclosporin A impairs the nocturnal blood pressure fall in renal transplant recipients. (1996) (67)
Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension. (1990) (67)
The Use of Desmopressin Acetate (DDAVP) as a Test of the Fibrinolytic Capacity of Patients – Analysis of Responders and Non-Responders (1982) (66)
WHO SHOULD BE CONVERTED FROM CYCLOSPORINE TO CONVENTIONAL IMMUNOSUPPRESSION IN KIDNEY TRANSPLANTATION, AND WHY (1987) (65)
Renal and Hepatic Handling of Endogenous Tissue-Type Plasminogen Activator (t-PA) and Its Inhibitor in Man (1988) (64)
Raised blood pressure and plasma noradrenaline concentrations in teenagers and young adults selected from an open population. (1979) (62)
Nonproteolytic "activation" of prorenin by active site-directed renin inhibitors as demonstrated by renin-specific monoclonal antibody. (1992) (62)
Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome. (1992) (61)
Functional importance of angiotensin-converting enzyme-dependent in situ angiotensin II generation in the human forearm. (2000) (60)
Cardiac interstitial fluid levels of angiotensin I and II in the pig. (1999) (59)
Angiotensin I‐to‐II conversion in the human renal vascular bed (1998) (59)
Improved immunoradiometric assay for plasma renin. (1999) (56)
Plasma renin and prorenin and renin gene variation in patients with insulin-dependent diabetes mellitus and nephropathy. (1999) (55)
Is there an internal cardiac renin-angiotensin system? (1996) (53)
Angiotensin-converting enzyme gene polymorphism and common carotid stiffness. The Rotterdam study. (2004) (53)
Abnormal Diurnal Variation of Blood Pressure, Cardiac Output, and Vascular Resistance in Cardiac Transplant Recipients (1994) (52)
Effects of chronic beta-adrenergic blockade on systemic and renal haemodynamic responses to hyperosmotic saline in hypertensive patients. (1972) (52)
Volume‐Pressure Relationships during Development of Mineralocorticoid Hypertension in Man (1977) (51)
ACTH-dependent aldosterone excess due to adrenocortical adenoma: a variant of primary aldosteronism. (1978) (50)
Sympathetic and parasympathetic components of reflex cardiostimulation during vasodilator treatment of hypertension. (1980) (47)
Effects of captopril in acute and chronic heart failure. Correlations with plasma levels of noradrenaline, renin, and aldosterone. (1983) (47)
Angiotensin I to angiotensin II conversion in the human forearm and leg. Effect of the angiotensin converting enzyme gene insertion/deletion polymorphism. (1999) (46)
Association of high plasma prorenin with diabetic retinopathy (1988) (45)
Hemodynamic and beta-adrenergic receptor adaptations during long-term beta-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients. (1989) (45)
Influence of sodium intake on hydrochlorothiazide-induced changes in blood pressure, serum electrolytes, renin and aldosterone in essential hypertension. (2009) (44)
Adrenal angiotensin: origin and site of generation. (2005) (43)
Determinants of short-term blood pressure variability. Effects of bed rest and sensory deprivation in essential hypertension. (1988) (43)
Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors (2008) (43)
Functional effects of renal artery stent placement on treated and contralateral kidneys. (2002) (43)
Human renal and systemic hemodynamic, natriuretic, and neurohumoral responses to different doses of L-NAME. (1998) (42)
Stress levels of adrenaline amplify the blood pressure response to sympathetic stimulation. (1986) (42)
Simultaneous determination of catecholamines and dobutamine in human plasma and urine by high-performance liquid chromatography with fluorimetric detection. (1992) (41)
Interrelationships between blood pressure, renin, renin substrate and blood volume in terminal renal failure. (1973) (41)
Effect of atrial natriuretic peptide on renal and vascular permeability in diabetes mellitus. (1995) (39)
Antihypertensive effects of propranolol. Observations on predictability. (1971) (39)
Consecutive haemodynamic patterns in essential hypertension. (1972) (39)
Human prorenin: pathophysiology and clinical implications. (1988) (38)
Angiotensin converting enzyme is the main contributor to angiotensin I–II conversion in the interstitium of the isolated perfused rat heart (2001) (38)
Blood pressure response of nephrectomized subjects and patients with essential hypertension to ramipril: indirect evidence that inhibition of tissue angiotensin converting enzyme is important. (1987) (37)
Intima-Media Thickness of the Common Carotid Arteries Is Related to Coronary Atherosclerosis and left Ventricular Hypertrophy in Older Adults (2002) (37)
Haemodynamic characteristics of low-renin hypertension. (1977) (37)
Nonparallel effects of renin inhibitor treatment on plasma renin activity and angiotensins I and II in hypertensive subjects. An assay-related artifact. (1991) (37)
Sensitivity and specificity of a new ELISA method for determination of chromogranin A in the diagnosis of pheochromocytoma and neuroblastoma. (1995) (36)
High concentrations of immunoreactive renin, prorenin and enzymatically‐active renin in human ovarian follicular fluid (1988) (36)
Long-term versus short-term effects of hydrochlorothiazide on renal haemodynamics in essential hypertension. (1979) (35)
Blood Pressure Components and Cardiovascular Events in Older Adults: The Rotterdam Study (2004) (35)
Glomerular hyperfiltration in insulin-dependent diabetes mellitus is correlated with enhanced growth hormone secretion. (1993) (34)
1 Pathogenesis of mineralocorticoid hypertension (1981) (34)
Plasma immunoreactive endothelin-1 in pregnant women with and without pre-eclampsia. (1991) (34)
Hemodynamic and hormonal adaptations to beta-adrenoceptor blockade. A 24-hour study of acebutolol, atenolol, pindolol, and propranolol in hypertensive patients. (1988) (33)
Hemodynamic effects of captopril in essential hypertension, renovascular hypertension and cardiac failure: correlations with short- and long-term effects on plasma renin. (1982) (32)
Angiotensin II production and distribution in the kidney: I. A kinetic model. (2006) (32)
Renal failure and cholesterol crystal embolization: a report of 4 surviving cases and a review of the literature. (1991) (32)
Intrarenal de novo production of angiotensin I in subjects with renal artery stenosis. (1990) (32)
Determination of semicarbazide-sensitive amine oxidase activity in human plasma by high-performance liquid chromatography with fluorimetric detection. (1995) (32)
Chronic Effect of Ketanserin in Mild to Moderate Essential Hypertension (1986) (31)
The Second Sir George Pickering Memorial Lecture What Regulates Whole Body Autoregulation? Clinical Observations (1985) (31)
Risks of angiotensin converting enzyme inhibition in renal artery stenosis. (1987) (30)
Haemodynamics, plasma noradrenaline and plasma renin in hypertensive and normotensive teenagers. (1981) (30)
Elevated plasma levels of endothelin in pre-eclampsia. (1991) (29)
The basal levels of active and inactive plasma renin concentration in infancy and childhood. (1984) (29)
Effect of synthetic human atrial natriuretic peptide (102-126) in nephrotic syndrome. (1988) (28)
The Inability of Propranolol and Aspirin to Inhibit the Response of Fibrinolytic Activity and Factor VIII-Antigen to Infusion of DDAVP (1984) (28)
Does captopril lower blood pressure in anephric patients? (1979) (28)
Evidence for activation of circulating inactive renin by the human kidney. (1979) (27)
Determination of aromatic-L-amino acid decarboxylase in human plasma. (1986) (27)
Body fluid volumes and the response of renin and aldosterone to short- and long-term thiazide therapy of essential hypertension. (2009) (27)
Optimising glomerular filtration rate and effective renal plasma flow measurements using a simple pharmacokinetic model. (1995) (27)
Plasma kallikrein and plasmin as activators of prorenin: links between the renin-angiotensin system and other proteolytic systems in plasma. (1981) (27)
Contrasting response to cyclosporin in refractory nephrotic syndrome. (1989) (26)
Simultaneous determination of free catecholamines and epinine and estimation of total epinine and dopamine in plasma and urine by high-performance liquid chromatography with fluorimetric detection. (1992) (26)
Prevention of epinephrine-induced hypokalemia by nonselective beta blockers. (1985) (25)
Haemodynamic Effects of Ketanserin, a Selective 5-Hydroxytryptamine (Serotonin) Receptor Antagonist, in Essential Hypertension (1982) (24)
Probing epitopes on human prorenin during its proteolytic and non-proteolytic activation. (1998) (24)
Letter: Renin and filtration fraction in essential hypertension. (1975) (24)
Comparison of N-terminal pro-atrial natriuretic peptide and atrial natriuretic peptide in human plasma as measured with commercially available radioimmunoassay kits. (1996) (24)
Conversion and degradation of [125I] labelled angiotensin I in isolated perfused porcine coronary and carotid arteries. (1995) (23)
Release of Active and Inactive Renin by the Porcine Kidney (1979) (23)
Diurnal variation of blood pressure in patients with catecholamine-producing tumors. (1994) (23)
The effect of beta blockers on total peripheral resistance. (1986) (22)
Increase in plasma prorenin during the menstrual cycle of a bilaterally nephrectomized woman (1990) (22)
Improved measurement of urinary catecholamines by liquid-liquid extraction, derivatization and high-performance liquid chromatography with fluorimetric detection. (1991) (22)
Theophylline and serum electrolytes. (1986) (22)
Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension (1993) (22)
Not norepinephrine but its oxidation products bind specifically to plasma proteins. (1991) (21)
Angiotensin II production and distribution in the kidney--II. Model-based analysis of experimental data. (2006) (21)
Effects of immunoscintigraphy with monoclonal antibodies in assays of hormones and tumour markers. (1989) (21)
Interrelations between arterial pressure, fluid-volumes, and plasma-renin concentration in the course of acute glomerulonephritis. (1970) (21)
Sero-immunological aspects of lens development in chick embryos. (1957) (21)
PATHOGENESIS OF ESSENTIAL HYPERTENSION (1976) (21)
Patients with Congenital Dopamine β-Hydroxylase DeficiencyA Lesson in Catecholamine Physiology (1988) (20)
DDAVP (1-desamino-8-D-arginine vasopressin): an antagonist of the pressor action of endogenous vasopressin? (1983) (20)
Renal insufficiency due to bilateral primary renal lymphoma. (1992) (20)
Is beta 1-antagonism essential for the antihypertensive action of beta-blockers? (1987) (20)
Effects of beta-adrenoceptor agonists and antagonists in patients with peripheral autonomic neuropathy. (1982) (20)
Induction of aromatic‐l‐amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism (1989) (19)
Circadian variation of heart rate but not of blood pressure after heart transplantation. (1987) (19)
Plasma kallikrein-mediated activation of the renin-angiotensin system does not require prior acidification of prorenin. (1982) (18)
Renin suppression in hypertension in relation to body fluid volumes, patterns of sodium excretion and renal haemodynamics. (1973) (18)
Renin inhibitors, angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: relationships between blood pressure responses and effects on the renin-angiotensin system. (1992) (17)
Treatment of idiopathic parkinsonism with l-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of l-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa (1989) (17)
Effects of DDAVP on renal hemodynamics and renin secretion in subjects with essential hypertension. (1994) (17)
Captopril affects blood pressure equally in renovascular and essential hypertension and in the fluid-depleted anephric state. (1980) (16)
Haemodynamic consequences of intrinsic sympathomimetic activity and cardioselectivity in beta-blocker therapy for hypertension. (1983) (16)
Dissociation of renin and aldosterone during dehydration: studies in a case of diabetes insipidus and adipsia. (1976) (16)
Role of plasma kallikrein in the proteolytic activation of the renin-angiotensin system. (1980) (16)
Assessment of the role of the renin‐angiotensin system in cardiac contractility utilizing the renin inhibitor remikiren (1996) (15)
Recurrence of hypertension in primary aldosteronism after discontinuation of spironolactone. Time course of changes in cardiac output and body fluid volumes. (1982) (15)
ADRENALINE, STRESS, AND HYPERTENSION (1983) (15)
Regional production of angiotensins I and II: contribution of vascular kidney-derived renin. (1991) (15)
Impaired fractional excretion of lithium: a very early marker of cyclosporine nephrotoxicity. (1987) (14)
New Renin Inhibitor VTP-27999 Alters Renin Immunoreactivity and Does Not Unfold Prorenin (2013) (14)
Ketanserin: a possible tool for studying the role of serotonin in hypertension. (1985) (14)
Evaluation of a Test Kit for the Rapid and Simple Colorimetric Measurement of Angiotensin I-Converting Enzyme in Serum (1983) (14)
Renin-angiotensin system components and endothelial proteins as markers of diabetic microvascular disease (2004) (14)
Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic-L-amino acid decarboxylase and semicarbazide-sensitive amine oxidase in Parkinson's disease. (1995) (14)
Combined measurements of plasma aromatic L-amino acid decarboxylase and DOPA as tumour markers in diagnosis and follow-up of neuroblastoma. (1989) (13)
How does the angiotensin II type 1 receptor ‘trump’ the type 2 receptor in blood pressure control? (2013) (13)
Cardioprotection by blockade of beta2-adrenoceptors (1983) (13)
Atrial natriuretic peptide in diabetic nephropathy. (1997) (13)
Decreased circadian blood pressure variation up to three years after heart transplantation. (1994) (12)
PATHOGENESIS OF ESSENTIAL HYPERTENSION (1976) (12)
Determination of 3,4-dihydroxyphenylalanine (DOPA) in plasma and cerebrospinal fluid by high performance liquid chromatography with electrochemical detection. (1988) (12)
Stability of human plasma atrial natriuretic peptide during storage at −80°C (1993) (12)
Patients with congenital dopamine beta-hydroxylase deficiency. A lesson in catecholamine physiology. (1988) (12)
Fractional excretion of protein: a marker of the efficacy of cyclosporine A treatment in nephrotic syndrome. (1988) (11)
Regulation of α- and β-adrenoceptor responsiveness: Studies in patients with chronic autonomic failure. (1983) (11)
More on renin. (1997) (11)
Quantitative radiocardiography by single-probe counting using 99mtechnetium albumin: clinical application in follow-up studies. (1978) (11)
Renal artery stenosis towards the year 2000. (1996) (11)
Systemic and renal vasodilation after beta-adrenoceptor blockade with pindolol: a hemodynamic study on the onset and maintenance of its antihypertensive effect. (1986) (11)
Inter-relationships between plasma angiotensin II, arterial pressure, aldosterone and exchangeable sodium in normotensive and hypertensive man. (1975) (11)
The adrenal cortex and hypertension: some observations on a possible role for mineralocorticoids other than aldosterone. (1976) (10)
Activators of inactive renin ("prorenin') in human plasma: their connection with kinin formation, coagulation and fibrinolysis. (1979) (10)
Acute Effects and Mechanism of Action of Ketanserin in Patients with Primary Raynaud's Phenomenon (1990) (10)
An Abnormal Relation Between Sodium and the Renin-Angiotensin System (1973) (10)
Prolonged cyclosporine therapy to induce solid engraftment after renal transplantation. (1987) (10)
Cyclosporin and the glomerular filtration barrier in minimal change disease and membranous glomerulopathy. (1995) (10)
HÆMODYNAMIC SETTING OF ESSENTIAL HYPERTENSION AS A GUIDE TO MANAGEMENT (1975) (9)
'Stress' levels of adrenaline mediate a protracted amplification of the blood pressure response to sympathetic stimulation in man. (1991) (9)
Estimation of regional metabolism and production of angiotensins in hypertensive subjects. (1989) (9)
Renin-angiotensin system: oral contraception and exercise in healthy female subjects. (1985) (9)
Ketanserin: haemodynamic effects and mechanism of action. (1986) (9)
Prorenin in vitreous and subretinal fluid of the human eye. (1988) (9)
Pathogenesis of mineralocorticoid hypertension. (1981) (9)
Does serotonin receptor blockade have a therapeutic effect in Raynaud's phenomenon? (1987) (8)
Maternal prolactin, cortisol, growth hormone and noradrenalin profiles during labor and following delivery. (1983) (8)
Beta-receptor stimulation by adrenaline elevates plasma noradrenaline and enhances the pressor responses to cold exposure and isometric exercise. (1983) (8)
Functional Diagnosis of Renovascular Hypertension, with Special Reference to Renin Measurements (1983) (8)
Changes in plasma renin and angiotensin run in parallel after nephrectomy (1993) (8)
Effect of isradipine on cyclosporin A-related hypertension. (1994) (8)
The rennin???angiotensin system: new surprises ahead (1991) (8)
Acute and Long-Term Effects of Acebutolol on Systemic and Renal Hemodynamics, Body Fluid Volumes, Catecholamines, Active Renin, Aldosterone, and Lymphocyte β-Adrenoceptor Density (1988) (7)
Mechanism of action of ketanserin in hypertension and vasospastic disease. (1987) (7)
A novel assay of plasma prorenin using a renin inhibitor (1993) (7)
Mechanism of antihypertensive action of ketanserin in man. (1983) (7)
ENDOGENOUS AND EXOGENOUS AGONIST REGULATION OF RESPONSES TO 0‐ADRENOCEPTOR STIMULATION IN PATIENTS WITH CHRONIC AUTONOMIC FAILURE (1982) (7)
Is β1-antagonism essential for the antihypertensive action of β-blockers? (1987) (7)
Prorenin-renin conversion by the contact activation system in human plasma: role of plasma protease inhibitors. (1984) (7)
The clinical pharmacology of bopindolol, a new long‐acting beta‐adrenoceptor antagonist, in hypertension (1987) (7)
Age dependency of blood pressure response to antihypertensive treatment: some methodological considerations and observations on five beta-adrenoceptor antagonists under different experimental conditions. (1988) (7)
Angiotensin converting enzyme: a tumour marker in malignant histiocytosis. (1983) (7)
Renin in the bovine eye. (1989) (7)
Epinephrine-induced enhancement of sympathetic activity in humans: inhibition by nonselective as well as beta 1-selective beta-adrenoceptor blockade. (1990) (6)
ANGIOTENSIN CONVERTING ENZYME INHIBITION IN RENOVASCULAR HYPERTENSION: FAILURE OF THE STENOTIC KIDNEY (1984) (6)
On the antihypertensive mechanisms of beta-adrenoceptor antagonists in relation to intrinsic sympathomimetic activity, cardioselectivity and hydrophilicity. (1983) (6)
Human renal and systemic hemodynamic, natriuretic, and neurohumoral responses to different doses ofl-NAME. (1998) (6)
Activation of plasma prorenin by plasminogen activators in vitro and increase in plasma renin after stimulation of fibrinolytic activity in vivo. (1982) (6)
Haemodynamics during long-term thiazide treatment in essential hypertension: differences between responders and non-responders. (1979) (5)
A local pre-receptor mechanism of hormone stimulus amplification: focus on angiotensin II in resistance blood vessels (2006) (5)
SIMPLIFIED METHOD FOR EVALUATING PROXIMAL TUBULAR FLUID REABSORPTION (1987) (5)
Cyclic blood pressure changes in a patient with a phaeochromocytoma: role of a central oscillator? (1985) (5)
First passage radionuclide cardiography for determination of cardiac output: a critical analysis. (1990) (5)
Second Björn Folkow Award Lecture. The renin-angiotensin system: new surprises ahead. (1991) (5)
Haemodynamic consequences of intrinsic sympathomimetic activity in relation to changes in plasma renin activity and noradrenaline during beta-blocker therapy for hypertension. (1983) (5)
Role of alpha-adrenergic blockade in the cardiovascular actions of ketanserin: studies in patients with essential hypertension, autonomic insufficiency, and Raynaud's phenomenon. (1987) (5)
Angiotensin II production in different vascular beds in hypertensive subjects. (1991) (5)
Determination of D,L-threo-3,4-dihydroxyphenylserine and of the D- and L-enantiomers in human plasma and urine. (1988) (5)
Direct 24-hour haemodynamic monitoring after starting beta-blocker therapy: studies with pindolol in hypertension. (1984) (5)
Venous versus arterial forearm catecholamines as an index of overall sympatho-adrenomedullary activity. (1989) (5)
Facilitated diffusion of angiotensin II from perivascular interstitium to AT1 receptors of the arteriole. A regulating step in vasoconstriction (2011) (5)
Release of active and inactive renin by the pig kidney during development. (1980) (5)
Sympathetic and parasympathetic components of reflex cardiostimulation during vasodilator treatment of hypertension. (1980) (4)
Time-course of vascular resistance changes in mineralocorticoid hypertension of man. (1981) (4)
Follow-up of renin in essential hypertension. (1976) (4)
Cardiac renin is kidney‐derived (1993) (4)
Use of captopril in the diagnostic work-up of renovascular hypertension. (1985) (4)
Impaired fractional excretion of lithium: an early marker of cyclosporine-induced changes in renal hemodynamics. (1988) (4)
Compound ICI 118,551, a beta 2-adrenoceptor antagonist, lowers blood pressure. (1985) (4)
Twenty‐four hour pressor effect of infused adrenaline in normotensive subjects: a randomized controlled double‐blind cross‐over study (1988) (4)
Comparison of the onset of the antihypertensive action of pindolol and propranolol. A 24 h haemodynamic study. (1987) (4)
Cardioprotection by blockade of beta 2-adrenoceptors. (1983) (4)
Angiotensin-converting enzyme inhibition does not correct early defects in renal and vascular permeability in diabetes mellitus. (1998) (4)
Comparison between the effects of ST 600 and clonidine. (1975) (4)
Breakdown of 3,4-dihydroxybenzylamine and dopamine in plasma of various animal species by semicarbazide-sensitive amine oxidase. (1993) (4)
Renal release of active and inactive renin in essential and renovascular hypertension. (1978) (4)
Comparison between the effects of ST 600 and catapres. (1975) (4)
Renal vein immunoreactive renin in patients with renal artery stenosis and essential hypertension. (1987) (4)
Role of intrinsic inhibitors in acid-activation of inactive plasma renin (prorenin). (1982) (3)
Circadian hemodynamics in heart transplant recipients (1993) (3)
High Activity of Semicarbazide‐Sensitive Amine Oxidase (SSAO): An Important Source of Errors in the Determination of the Concentration of Dopamine in Pig Plasma (1993) (3)
Acute and long-term effects of acebutolol on systemic and renal hemodynamics, body fluid volumes, catecholamines, active renin, aldosterone, and lymphocyte beta-adrenoceptor density. (1988) (3)
Adrenaline‐induced amplification of sympathetic activity during rest and stress: inhibition by non‐selective and beta1-selective beta‐adrenoceptor blockade (1988) (3)
1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus. (1993) (3)
The plasma kallikrein-renin connection. (1980) (3)
Renin levels in hypertension. (1972) (3)
Volume control. (1972) (3)
The early pathogenesis of primary hypertension : proceedings of the International Symposium on Primary Hypertension, Implications for Detection and Intervention in Childhood, Rotterdam, 9-10 September 1986 (1987) (3)
Glomerular barrier function following conversion from cyclosporine to azathioprine in renal transplant recipients. (1994) (3)
Two forms of plasma renin after activation in vitro and their relation to natural plasma renin. (1981) (2)
Captopril in the diagnostic work-up of hypertensive patients with suspected renal artery stenosis. (1993) (2)
Distribution of Extracellular Fluid Over the Intra- and Extravascular Space in Hypertensive Patients (1984) (2)
Effects of Ibopamine on Postural Hypotension in Pure Autonomie Failure (1993) (2)
Comparison of the acute and chronic antihypertensive effect of two once-daily doses of spirapril by invasive twenty-four-hour ambulatory blood pressure monitoring. (1989) (2)
THE FIBRINOLYTIC, FACTOR VIII:C, VON WILLEBRAND FACTOR AND HEMODYNAMIC RESPONSES TO DDAVP IN PATIENTS WITH HEREDITARY NEPHROGENIC DIABETES INSIPIDUS (1987) (2)
Uptake and intracellular activation of prorenin in human endothelial cells (1995) (2)
Renal secretion of inactive renin. (1978) (2)
Evidence for the existence of a functional cardiac renin-angiotensin system in humans. (1997) (2)
Nebivolol: An Acute and Long Term Study in Essential Hypertension (1991) (2)
Age-related differences in the long-term responses of systemic flow and resistance to mineralocorticoid excess in man. (1980) (2)
Angiotensin I-converting enzyme in the diagnosis and management of sarcoidosis. (1981) (2)
Does captopril improve the diagnostic value of 99mTc‐diethylenetriaminepentaacetic acid renography for renal artery stenosis? (1993) (2)
Ketanserin in hypertension and vasospastic disease : mechanism of action (1990) (2)
Haemodynamic profile of captopril treatment in various forms of hypertension (2004) (2)
Stability of human plasma atrial natriuretic peptide during storage at -80 degrees C. (1993) (2)
RENIN AND FILTRATION FRACTION IN ESSENTIAL HYPERTENSION (1975) (2)
Dihydroergotoxine (hydergine) to prevent cyclosporine nephrotoxicity in kidney transplant recipients. (1987) (2)
Ambulatory assessment of the acute and chronic antihypertensive effect of spirapril, a new ACE inhibitor (1989) (2)
Mono-aminergic receptors and blood pressure. (1985) (1)
Renin levels and cardiovascular morbidity in essential hypertension. A prospective study. (1977) (1)
Haemodynamic changes during reversible hypertension due to liquorice ingestion. (1973) (1)
Preferential Desensitization to Cardiovascular β2-Adrenoceptor Stimulation in Patients with Peripheral Autonomic Neuropathy after Treatment with Pindolol (1982) (1)
Acute and long‐term haemodynamic effects of bopindolol in hypertension (1988) (1)
Follow-up of renin in essential hypertension. (1976) (1)
Plasma Kallikrein as an Activator of Inactive Renin ("Prorenin") - Studies In-Vitro and In-Vivo (1980) (1)
DISTRIBUTION OF CYTOSKELETAL PROTEINS (CP), INTEGRINS (IG) AND EXTRACELLULAR-MATRIX PROTEINS (ECM) IN PLASTIC EMBEDDED HUMAN AND RAT KIDNEYS (1992) (1)
Components of the rennin angiotensin system in vitreous fluid from eyes with and without diabetic retinopathy (1989) (1)
In vivo production of plasma angiotensin I: is plasma renin sufficient? (1989) (1)
Adrenaline-induced amplification of sympathetic activity during rest and stress: inhibition by non-selective and beta 1-selective beta-adrenoceptor blockade. (1988) (1)
Haemodynamics of renoprival hypertension in man: studies during graded fluid withdrawal. (1980) (1)
ACTIVATION OF PRORENIN BY PLASMA KALLIKREIN AND PLASMIN (1983) (1)
Epinephrine‐Induced Enhancement of Sympathetic Activity in Humans: Inhibition by Nonselective as Well as β1-Selective β‐Adrenoceptor Blockade (1990) (1)
Specific binding of catecholamines to plasma proteins: fact or artefact? (1991) (1)
Systemic and renal haemodynamics during antihypertensive treatment with propranolol. (1973) (1)
Face to Face (PDF) (1977) (0)
Friday, May 19, 12:15 pmHigh serum prorenin is a risk factor for micro-albuminuria in patients with insulin-dependent diabetes mellitus. a 10-year follow-up study. (1995) (0)
Relevance of prorenin as a marker of pathophysiology in diabetes mellitus (1994) (0)
1047 SECRETION OF ACTIVE AND INACTIVE RENIN BY THE DEVELOPING KIDNEY (1978) (0)
223 Slow renin inhibitor-induced conformational change in recombinant human prorenin: a possible model for substrate-mediated pro-enzyme activation (1993) (0)
Can angiotensin II cause renal hypertension when its plasma concentration is normal? (1977) (0)
30. Enzymatically active plasma prorenin: does it exist? (1991) (0)
Proceedings: Relationship between angiotensin II and sodium status in the control of blood pressure: studies in anephric subjects and in subjects with renal hypertension. (1976) (0)
[Renovascular hypertension, still a problem]. (1978) (0)
Pindolol acts as beta-adrenoceptor agonist in orthostatic hypotension. (1981) (0)
A longitudinal study of the hypertensive process in man. (1977) (0)
Plasma prorenin and diabetic retinopathy (1989) (0)
Role of α‐Adrenergic Blockade in the Cardiovascular Actions of Ketanserin: Studies in Patients with Essential Hypertension, Autonomie Insufficiency, and Raynaud's Phenomenon (1987) (0)
Hypertensive emergencies. (2005) (0)
[Various aspects of metabolism during long term fasting]. (1971) (0)
Captopril in the Treatment of Hypertension with Renal Artery Stenosis (1983) (0)
Is human atrial natriuretic peptide unstable at -80 degrees C? (1993) (0)
Release of angiotensin I from tissue sites into the systemic and cardiopulmonary circulations (1990) (0)
[Hypertension caused by arterial fibromuscular dysplasia]. (1994) (0)
[Monotherapy with antihypertensive drugs: can a choice be made?]. (1992) (0)
[Clinical significance of plasma renin determinations in disorders of renal circulation]. (1970) (0)
Renal-clip hypertension. (1970) (0)
55 Measurement of cardiac production of natriuretic factor in untreated pre‐eclampsia (1988) (0)
CARDIOMYOCYTES BIND AND ACTIVATE NATIVE HUMAN PRORENIN: P3.221 (2000) (0)
Is human atrial natriuretic peptide unstable at −80°C? (1993) (0)
REVERSIBILITY OF CICLOSPORIN RELATED SIDE EFFECTS IN ADULT RECIPIENTS AFTER ONE YEAR OF CONTINUOUS THERAPY (1986) (0)
Prorenin, renin and the ovary (1989) (0)
Human Endothelial Cells Bind and Activate Noncleavable Prorenin (2000) (0)
[A patient with a wide aorta and 2 wide kidney pelves: retroperitoneal fibrosis]. (1991) (0)
Activation of plasma prorenin by plasminogen activators in vitro and increase in plasma renin after stimulation of fibrinolytic activity in vivo. (1984) (0)
Response to 'Angiotensin II type 1 and type 2 receptor interplay in hypertension: lesson from a human model of vascular hyporeactivity'. (2013) (0)
Subjects With Hypertrophic Cardiomyopathy Polymorphism Contributes to Cardiac Hypertrophy in 1166 Receptor (1998) (0)
activation to renin man-6-P/IGF-II receptors precedes proteolytic High-affinity prorenin binding to cardiac (2006) (0)
A novel approach for the measurement of prorenin in plasma and follicular fluid (1994) (0)
A neonate with idiopathic hyperaldosteronism (1991) (0)
[Routine determination of serum digoxin and theophylline levels; no superfluous luxury]. (1984) (0)
Cardiomyocytes Bind and Activate Renal But not Non-Renal Human Prorenin. (2000) (0)
Generation and Localization of Angiotensin II in the Heart (1998) (0)
Correction: Pindolol acts as beta-adrenoceptor agonist in orthostatic hypotension (1981) (0)
[A new point of attack for the treatment of hypertension; captopril, an orally active inhibitor of the enzymatic conversion of angiotensin I into angiotensin II]. (1980) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Maarten A. D. H. Schalekamp?

Maarten A. D. H. Schalekamp is affiliated with the following schools:

Erasmus University Rotterdam